News and Announcements
Turning Investor Rejection into Opportunity: How to Leverage a “No” for Future Success
- Published June 18, 2023 11:00PM UTC
- Publisher Steve Torso
- Categories Capital Raising Tips
Receiving a rejection from an investor can feel disheartening, but what if I told you it could actually be a valuable asset? In this enlightening video, we delve into the art of transforming investor rejection into a powerful advantage for your future fundraising endeavors.
Getting a “no” from an investor is not only common but also inevitable. Rather than letting it discourage you, learn how to leverage that rejection to your advantage. We share proven strategies and insights that will enable you to harness the power of a “no” and turn it into a stepping stone towards success.
Join us as we guide you through the process of reframing rejection and utilising it as a valuable resource in your future investor discussions. Discover how to extract valuable feedback, refine your pitch, and approach future investors with renewed confidence.
Don’t let investor rejection hold you back. Embrace the opportunity it presents and gain a competitive edge in your fundraising journey. Watch this video now and learn how to transform a “no” into a powerful asset for future investor engagements.
Capital Raising Tips
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
